In previous studies, researchers have demonstrated that treatment with a CXCR2 antagonist (SB225002) inhibits the tumour cell invasive properties of lung adenocarcinomas [23] and suppresses the tumour growth of intrahepatic cholangiocellular carcinomas [54]. Here, CXCR2 is linked to lung adenocarcinoma.